Phase 4 N=140 Randomized Double-blind Treatment

Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients

Non-ST Elevation Myocardial Infarction

Bottom Line

View on ClinicalTrials.gov: NCT03114995 ↗

Enrolled (actual)

140

Serious AEs

0.0%

Results posted

Jun 2018

Primary outcome: Primary: Area Under Curve of Serial Cardiac Biomarkers — 197.2; 38.0; 121.4; 252.5 Hours*ng/ml

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Tirofiban (Drug)
Age: Adult, Older Adult · 19+ yrs
Sex: All
Sponsor: Seoul National University Bundang Hospital
Primary completion: Oct 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Area Under Curve of Serial Cardiac Biomarkers	197.2; 38.0; 121.4; 252.5; 92.7; 185.6	—
SECONDARY Percentage of Participants With Periprocedural Myonecrosis	16; 15; 26; 11; 10; 25	—

Summary

Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.

Eligibility Criteria

Inclusion Criteria

diagnosed with NSTE-ACS who need PCI
loaded with aspirin and clopidogrel at least 6 h before the procedure

Exclusion Criteria

thrombocytopenia (platelet count <100,000/μL)
history of hemorrhagic stroke
history of ischemic stroke in the recent 2 year
history of major surgery 6 months prior

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03114995). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.